Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
1.36
Dollar change
-0.02
Percentage change
-1.81
%
Index- P/E- EPS (ttm)-1.40 Insider Own12.70% Shs Outstand18.60M Perf Week-8.45%
Market Cap28.28M Forward P/E- EPS next Y-0.59 Insider Trans0.00% Shs Float18.22M Perf Month5.04%
Income-25.99M PEG- EPS next Q-0.22 Inst Own2.21% Short Float0.64% Perf Quarter-3.21%
Sales0.00M P/S- EPS this Y48.08% Inst Trans-12.09% Short Ratio1.57 Perf Half Y-49.25%
Book/sh1.43 P/B0.95 EPS next Y27.16% ROA-57.08% Short Interest0.12M Perf Year-46.65%
Cash/sh1.13 P/C1.20 EPS next 5Y- ROE-67.14% 52W Range1.15 - 4.59 Perf YTD-49.81%
Dividend Est.- P/FCF- EPS past 5Y32.51% ROI-94.72% 52W High-70.48% Beta0.98
Dividend TTM- Quick Ratio7.86 Sales past 5Y0.00% Gross Margin- 52W Low17.83% ATR (14)0.10
Dividend Ex-Date- Current Ratio7.86 EPS Y/Y TTM14.41% Oper. Margin0.00% RSI (14)44.96 Volatility5.32% 6.84%
Employees49 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price6.00
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q43.28% Payout- Rel Volume0.64 Prev Close1.38
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsMay 24 Avg Volume74.80K Price1.36
SMA20-2.25% SMA50-3.43% SMA200-37.73% Trades Volume47,755 Change-1.81%
Date Action Analyst Rating Change Price Target Change
Mar-02-21Reiterated H.C. Wainwright Buy $22 → $33
Jul-19-24 09:00AM
Jun-24-24 08:00AM
Jun-20-24 08:00AM
Jun-17-24 08:00AM
Jun-03-24 08:00AM
04:15PM Loading…
May-29-24 04:15PM
May-28-24 08:12AM
Apr-29-24 08:00AM
Apr-22-24 08:00AM
Apr-16-24 07:50AM
Apr-15-24 01:01PM
Apr-11-24 02:58PM
08:05AM
Apr-05-24 07:52AM
Mar-22-24 10:50AM
08:30AM Loading…
Feb-26-24 08:30AM
Feb-21-24 08:30AM
Feb-07-24 08:00AM
Jan-17-24 08:00AM
Dec-20-23 08:00AM
Nov-21-23 07:00AM
Sep-11-23 08:00AM
Sep-07-23 08:00AM
Aug-02-23 08:00AM
Jul-31-23 08:00AM
Jun-26-23 08:00AM
Jun-06-23 08:00AM
May-31-23 08:04AM
May-08-23 08:00AM
Apr-20-23 10:18AM
08:00AM Loading…
Apr-19-23 08:00AM
Apr-17-23 08:00AM
Apr-14-23 09:40AM
Apr-12-23 10:45AM
Apr-10-23 03:07AM
Apr-04-23 08:00AM
Apr-03-23 08:00AM
Mar-20-23 08:00AM
Feb-23-23 08:00AM
Feb-15-23 08:00AM
Jan-25-23 08:37AM
Jan-04-23 08:00AM
Dec-05-22 08:00AM
Dec-02-22 08:00AM
Dec-01-22 02:00PM
Nov-28-22 08:00AM
Nov-15-22 08:00AM
Nov-11-22 09:05AM
Nov-10-22 08:00AM
Oct-03-22 08:13AM
Sep-13-22 08:00AM
Sep-12-22 08:00AM
Sep-06-22 08:00AM
Aug-29-22 08:00AM
Aug-24-22 08:00AM
Aug-22-22 08:00AM
Aug-17-22 08:00AM
Aug-03-22 08:15AM
Jul-12-22 09:05AM
Jul-06-22 08:37AM
Jun-07-22 08:00AM
Jun-06-22 08:00AM
Jun-04-22 09:45AM
May-31-22 08:00AM
May-25-22 08:00AM
May-23-22 08:00AM
May-19-22 08:00AM
May-10-22 08:00AM
May-09-22 09:05AM
May-05-22 08:37AM
May-02-22 08:00AM
Apr-29-22 08:41AM
Apr-13-22 10:25AM
Mar-08-22 08:00AM
Mar-01-22 07:30AM
Feb-22-22 08:00AM
Jan-03-22 08:00AM
Dec-26-21 07:22AM
Dec-14-21 03:26PM
Dec-13-21 08:00AM
Dec-07-21 08:00AM
Dec-06-21 08:00AM
Nov-22-21 08:00AM
Nov-10-21 08:00AM
Nov-04-21 08:00AM
Oct-12-21 08:00AM
Oct-05-21 08:00AM
Oct-04-21 08:00AM
Sep-29-21 08:48AM
Sep-27-21 06:38AM
Sep-23-21 10:02AM
Sep-22-21 06:00AM
Sep-09-21 08:00AM
Sep-03-21 12:00PM
Aug-16-21 02:32PM
12:13PM
08:31AM
08:20AM
07:20AM
07:07AM
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.